静脉铁剂在肾性贫血中的临床应用进展  

Progress of clinical application of intravenous iron in renal anemia

作　　者：刘畅[1] 范瑛 汪年松[2] LIU Chang;FAN Ying;WANG Niansong(Department of Geriatrics,Shanghai Sixth People's Hospital Affliated to Shanghai Jiao Tong University,Shanghai 200233,China;Department of Nephrology,Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200233,China)

机构地区：[1]上海交通大学医学院附属第六人民医院老年病科,上海200233 [2]上海交通大学医学院附属第六人民医院肾脏内科,上海200233

出　　处：《世界临床药物》2025年第1期19-22,共4页World Clinical Drug

基　　金：国家自然基金面上项目(82270761);国家重点研发计划(2023YFC2411803);上海市重中之重研究中心建设项目[2022ZZ01002(3)];上海市进一步加快中医药传承创新发展三年行动计划[ZY(2021-2023)-0205-04]。

摘　　要：慢性肾脏病(chronic kidney disease)患者临床常见铁代谢紊乱(iron metabolism disorder),常导致肾性贫血(renal anemia,RA)。静脉铁剂是目前RA的重要治疗手段,常用药物包括羧基麦芽糖铁(ferric carboxymaltose)、纳米氧化铁(ferumoxytol)及异麦芽糖酐铁(ferric derisomaltose)等。该文基于既往研究成果,对静脉铁剂在RA中的应用进展作一综述,以期为个体化铁剂治疗提供一定思路。Iron metabolism disorder is common disorder in patients with chronic kidney disease,which leads to renal anemia(RA).Intravenous iron is an important treatment for RA,and commonly used drugs include ferric carboxymaltose,ferumoxytol and ferric derisomaltose.Based on the previous research results,this article reviewed the application progress of intravenous iron in RA,in order to provide some ideas for individualized iron therapy.

关 键 词：静脉铁剂 肾性贫血 慢性肾脏病 

分 类 号：R692.5[医药卫生—泌尿科学] R692[医药卫生—外科学]